A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-06 and is reviewed periodically as new material appears.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
=== Honors College === The University of Arizona W.A. Franke Honors College provides a program for over 4,500 students that creates a smaller community feel like that of a liberal arts college within a large research institution. It started in 1962 with an acceptance of seventy-five students and has grown to 5,508 in the academic year 2016–2017. It was renamed from the Honors College to the W.A. Franke Honors College in recognition of a $25 million gift commitment made by William A. "Bill" Franke.
== Overdose == Overdose symptoms can be confusion, hypotension, and tachycardia, and several fatalities have been reported with concentrations in postmortem blood ranging from 0.1 to 7.0 mg/L compared to non-toxic levels in postmortem blood which can extend to 0.4 mg/kg.
P.H., professor in the Department of Biostatistics in the UAB School of Public Health George Howard explains that "Asking someone how much they weigh is probably the second worst question behind how much money they make," "From past research, we know that women tend to under-report their weight, and men tend to over-report their height." Howard said as far as equivalency between the self-reported and measured data sets, the East South Central region showed the least misreporting. "This suggests that people from the South come closer to telling the truth than people from other regions, perhaps because there's not the social stigma of being obese in the South as there is in other regions." The area of the United States with the highest obesity rate is American Samoa (75% obese and 95% overweight).
=== Characteristics of elution mode === In elution mode, solutes are applied to the column as narrow bands and, at low concentration, move down the column as approximately Gaussian peaks. These peaks continue to broaden as they travel, in proportion to the square root of the distance traveled. For two substances to be resolved, they must migrate down the column at sufficiently different rates to overcome the effects of band spreading. Operating at high concentration, where the isotherm is curved, is disadvantageous in elution chromatography because the rate of travel then depends on concentration, causing the peaks to spread and distort. Retention in elution chromatography is usually controlled by adjusting the composition of the mobile phase (in terms of solvent composition, pH, ionic strength, and so forth) according to the type of stationary phase employed and the particular solutes to be separated. The mobile phase components generally have lower affinity for the stationary phase than do the solutes being separated, but are present at higher concentration and achieve their effects due to mass action. Resolution in elution chromatography is generally better when peaks are strongly retained, but conditions that give good resolution of early peaks lead to long run-times and excessive broadening of later peaks unless gradient elution is employed. Gradient equipment adds complexity and expense, particularly at large scale.
Sources: en.wikipedia.org
There has been a growing interest in the application of ion chromatography in the analysis of pharmaceutical drugs. Ion chromatography is used in different aspects of product development and quality control testing. For example, ion chromatography is used to improve stabilities and solubility properties of pharmaceutical active drugs molecules as well as used to detect systems that have higher tolerance for organic solvents. Ion chromatography has been used for the determination of analytes as a part of a dissolution test. For instance, calcium dissolution tests have shown that other ions present in the medium can be well resolved among themselves and also from the calcium ion. Therefore, ion chromatography has been employed in drugs in the form of tablets and capsules in order to determine the amount of drug dissolve with time. Ion chromatography is also widely used for detection and quantification of excipients or inactive ingredients used in pharmaceutical formulations. Detection of sugar and sugar alcohol in such formulations through ion chromatography has been done due to these polar groups getting resolved in ion column. Ion chromatography methodology also established in analysis of impurities in drug substances and products. Impurities or any components that are not part of the drug chemical entity are evaluated and they give insights about the maximum and minimum amounts of drug that should be administered in a patient per day.
=== Leaves === The leaf outline is mostly ovate to rhomboid. The outline can sometimes be elliptic or obovate. The leaf margin is dentate or deeply lobed. The indumentum of the leaves can vary. There is often a hairy upper surface, and the lower surface can be sparsely to densely hairy. It has been described as feeling velvety. When the leaves are crushed, there is an unpleasant scent. This may be due to the pelate hairs or pelate glands on the leaves. The leaves are opposite whorls of 3–4. The petiole is 0–24 mm long.
In November 2019, he imposed a moratorium on approval of new hydraulic fracturing and steam-injected oil drilling in the state until the permits for those projects could be reviewed by an independent panel of scientists. State agencies resumed issuing new hydraulic fracturing permits in April 2020. In 2021, the Center for Biological Diversity sued the Newsom administration over the continued sale of oil and gas leases, and Consumer Watchdog called for the end of their sale. In April 2021, Newsom committed to ending the sale of gas leases by 2024 and ending oil extraction by 2045. In October 2021, he proposed a 3,200-foot (980 m) buffer between new fossil fuel extraction sites and densely populated areas. In 2022, gas prices in California exceeded $6 per gallon. Newsom attributed this to corporate greed and price gouging by oil companies. He proposed a windfall profits tax and penalty for oil companies in September 2022. On March 28, 2023, Newsom signed a law that authorizes the California Energy Commission to set "a profit threshold above which companies would be assessed a financial penalty", requires petroleum companies to report additional profit data to state regulators, and creates a new oversight division of the California Energy Commission to investigate price gouging in the gasoline industry. In June 2025, Newsom signed California Assembly Bill 130 (2025) into law. In October 2025, Newsom vetoed Senate Bill 682 which sought to limit forever chemicals and Assembly Bill 93 which sought to require data centers to report their water use.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.